Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
ASRT Stock Chart & Stats
$0.79
-$0.03(-3.72%)
At close: 4:00 PM EST
$0.79
-$0.03(-3.72%)
Day’s Range― - ―
52-Week Range$0.51 - $1.08
Previous CloseN/A
Volume363.47K
Average Volume (3M)295.13K
Market Cap
$69.79M
Enterprise Value$9.14M
Total Cash (Recent Filing)$93.43M
Total Debt (Recent Filing)$39.17M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 11, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding96,239,624
10 Day Avg. Volume250,113
30 Day Avg. Volume295,133
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.69
Price to Sales (P/S)0.66
P/FCF Ratio3.14
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.10
Enterprise Value/Ebitda1.54
Forecast
1Y Price Target
$3.00Price Target Upside279.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
LeadershipMark L. Reisenauer, previously a board member at Assertio, became the new CEO with extensive experience in business development and commercializing oncology products.
Product Market ShareAssertio maintained a leading market share in its chosen segment and expects uninterrupted patient supply.
Revenue PerformanceAssertio reported 3Q25 results with total revenue of $49.5M, above consensus of $27.0M and our estimate of $27.9M.
Bears Say
Cash BalanceThe cash balance is expected to decline in the next two quarters as the inventory balance normalizes and due to timing impacts of cash collections.
CompetitionIndocin net product sales were down from the prior-year quarter, reflecting expected volume and pricing impacts from previously announced generic competition.
Market Share RisksRisks include inability to obtain additional market share for ROLVEDON and Sympazan, greater-than-anticipated levels of competition, and possible long-term dilution risk.
Assertio Therapeutics News
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.51 and its highest was $1.08 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Assertio Therapeutics Inc’s market cap is $69.79M.
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 113 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Nov 10, 2025. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.195.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -0.21.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 96,239,624 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of $0.11 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went up 15%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Currently, no hedge funds are holding shares in ASRT
Assertio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (279.75% Upside)
$3.00 (279.75% Upside)
Hedge Fund Trend
Decreased
By 75.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.03%
12-Months-Change
Fundamentals
Return on Equity
-24.48%
Trailing 12-Months
Asset Growth
-2.03%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. (ASRT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with pain and other neurological disorders. The company operates primarily in the pharmaceutical sector, with a product portfolio that includes prescription medications designed to address unmet medical needs in pain management and neurological conditions. Assertio aims to enhance patient outcomes through its proprietary formulations and targeted therapies.
ASRT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant growth in Rolvedon sales and market share, alongside strategic product advancements, contributing to a strong financial position. However, challenges such as the decline in Indocin sales due to generic competition and temporary cash flow impacts from sales pull-forwards were noted, alongside costs related to the decommercialization of Otrexup.View all ASRT earnings summariesASRT Stock 12 Month Forecast
Average Price Target
$3.00
▲(279.75% Upside)
Technical Analysis
Ownership Overview
1.99% Insiders
6.15% Mutual Funds
0.05% Other Institutional Investors
87.49% Public Companies and
Individual Investors